Metadon Martindale Pharmaceuticals (Methadone Hydrochloride)

Methadone works by binding strongly to the µ‑opioid receptors in the central nervous system, acting as a full agonist. This activation reduces pain signals and suppresses the cravings and withdrawal associated with opioid dependence, while its long half‑life maintains steadier drug levels.

The appropriate dose of Metadon is individualized. A qualified prescriber determines the starting amount, titration schedule, and maintenance dose based on the patient’s clinical condition, prior opioid exposure, and response to therapy.

Methadone is classified as Pregnancy Category C, meaning risk cannot be ruled out. It may be used when the benefit outweighs potential harm, but careful monitoring is required. During breastfeeding, caution is advised because the drug can pass into milk and affect the infant.

To order Metadon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative for opioid dependence is buprenorphine, a partial µ‑opioid agonist. Methadone provides full agonism and a longer half‑life, which can offer more stable plasma levels but carries a higher risk of respiratory depression. Choice depends on patient history, treatment goals and clinician judgment.

Metadon should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and excessive heat to maintain potency. Keep out of reach of children and unauthorized personnel.

Metadon is administered orally. The tablet or capsule is swallowed whole with water, usually once daily for maintenance therapy, although dosing frequency may be adjusted by the prescriber based on therapeutic response and plasma levels.

The most serious risks include respiratory depression, especially when combined with other depressants, QT‑interval prolongation that can lead to cardiac arrhythmias, and the potential for overdose. Patients should be monitored closely for signs of severe sedation, breathing difficulties or cardiac symptoms.

Metadon is contraindicated in individuals with known hypersensitivity to methadone, severe respiratory depression, acute asthma attacks, or those taking monoamine oxidase inhibitors (MAOIs). Caution is also required for patients with significant cardiac disease, liver impairment, or a history of substance misuse.